文献速递急性肾损伤慢性肾脏病

静脉造影剂致肾病争议:风险究竟如何?

The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk?
PubMed 文献 · Am J Kidney Dis · 2019-08-28

本文综述静脉造影剂相关造影剂肾病(CIN)的争议,指出早期研究缺乏对照或未校正慢性肾脏病等混杂因素,现代倾向评分模型仍存选择偏倚。作者基于现有数据提出CIN风险分层:eGFR≥45mL/min/1.73m²风险可忽略,eGFR<30mL/min/1.73m²为高风险,eGFR 30-44mL/min/1.73m²为中风险(合并糖尿病则风险进一步升高)。

要点

  • eGFR≥45mL/min/1.73m²者静脉造影后CIN风险可忽略。
  • eGFR<30mL/min/1.73m²者静脉造影后CIN高风险。
  • eGFR 30-44mL/min/1.73m²为中风险,合并糖尿病风险更高。

核心结论

  • 基于现有数据提出静脉造影剂CIN风险分层,强调需权衡造影检查风险与不检查风险。

研究设计与样本

  • 综述性文章,总结实验与临床研究及近期观察性研究,讨论CIN患病率与严重性争议。

主要发现

  • 早期静脉造影后急性肾损伤研究缺乏对照或未校正慢性肾脏病等危险因素及预防策略。
  • 现代倾向评分校正模型试图减少选择偏倚,但无前瞻性随机试验无法完全消除偏倚。

关键数值与推荐

  • eGFR≥45mL/min/1.73m²者CIN风险可忽略。
  • eGFR<30mL/min/1.73m²者CIN高风险。
  • eGFR 30-44mL/min/1.73m²者CIN中风险,合并糖尿病则风险进一步升高。

临床怎么用

  • 按eGFR及是否合并糖尿病对静脉造影患者进行CIN风险分层。
  • 对任何CIN风险升高者,需权衡造影检查风险与不进行造影检查的风险。

局限性

  • 现有观察性研究存在选择偏倚,缺乏前瞻性随机试验完全消除偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Contrast-induced nephropathy (CIN) has long been observed in both experimental and clinical studies. However, recent observational studies have questioned the prevalence and severity of CIN following intravenous contrast exposure. Initial studies of acute kidney injury following intravenous contrast were limited by the absence of control groups or contained control groups that did not adjust for additional acute kidney injury risk factors, including prevalent chronic kidney disease, as well as accepted prophylactic strategies. More contemporary use of propensity score-adjusted models have attempted to minimize the risk for selection bias, although bias cannot be completely eliminated without a prospective randomized trial. Based on existing data, we recommend the following CIN risk classification: patients with estimated glomerular filtration rates (eGFRs) ≥ 45mL/min/1.73m2 are at negligible risk for CIN, while patients with eGFRs<30mL/min/1.73m2 are at high risk for CIN. Patients with eGFRs between 30 and 44mL/min/1.73m2 are at an intermediate risk for CIN unless diabetes mellitus is present, which would further increase the risk. In all patients at any increased risk for CIN, the risk for CIN needs to be balanced by the risk of not performing an intravenous contrast-enhanced study.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Rudnick MR, Leonberg-Yoo AK, Litt HI, et al. The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk? Am J Kidney Dis. 2019. PMID: 31473019. doi:10.1053/j.ajkd.2019.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。